J Korean Diabetes Assoc.  2006 Sep;30(5):398-402. 10.4093/jkda.2006.30.5.398.

Clinical Courses of Two Women with Gestational Diabetes Mellitus Who are GAD Antibody Positive

• Yu SH
• Song MJ
• Kim SH
• Yim CH
• Han KO
• Park WK
• Yoon HK
• Chung HY

• KMID: 2008270
• DOI: http://doi.org/10.4093/jkda.2006.30.5.398

Abstract

Gestational diabetes mellitus (GDM) is defined as glucose intolerance of various degrees with onset or first recognition during pregnancy. Women with GDM are at high risk of developing type 2 diabetes later in life, but the risk of developing type 1 diabetes is also increased. Positivity for glutamic acid decarboxylase (GAD) antibodies during pregnancy confers a high risk for subsequent progression to type 1 diabetes. Here, we reported the two cases with GDM who were GAD antibody positive and progressed to type 1 diabetes with different time-courses. One woman with GDM progressed rapidly to classical type 1 diabetes while the other became slowly progressive IDDM (SPIDDM) [or latent autoimmune diabetes in adults (LADA)].

Keyword

GAD antibody; Gestational diabetes mellitus; Type 1 diabetes

MeSH Terms

Adult
Antibodies
Diabetes Mellitus, Type 1
Diabetes, Gestational*
Female
Glucose Intolerance
Glutamate Decarboxylase
Humans
Pregnancy
Antibodies
Glutamate Decarboxylase

Figure

• 

  Fig. 1 Plasma glucose and insulin concentrations during 100 g oral glucose tolerance test (OGTT) at 25th weeks of pregnancy in two cases.

• 

  Fig. 2 Plasma glucose and insulin concentrations during 75 g oral glucose tolerance test (OGTT) at postpartum 6 weeks in two cases.

Reference

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003. 26:S5–S20.

2. American Diabetes Association. Gestational diabetes mellitus (Position Statement). Diabetes Care. 2004. 27:S88–S90.

3. Metzger BE, Coustan DR. Organizing Committee. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 1998. 21:B161–B167.

4. American College of Obstetrics and Gynecologists Committee on Practice Bulletins-Obstetrics. Gestational diabetes. Obstet Gynecol. 2001. 98:525–538.

5. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care. 2002. 25:1862–1868.

6. Cheung NW, Byth K. Population health significance of gestational diabetes. Diabetes Care. 2003. 26:2005–2009.

7. Fuchtenbusch M, Ferber K, Standl E, Ziegler AG. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes. 1997. 46:1459–1467.

8. Vaughan JE, Raochod HA. Incidence of gestational diabetes at northen hospital. Diabetes. 1991. 40:414.

10. Jang HC, Cho NH, Jung KB, Oh KS, Dooley SL, Metzger BE. Screening for gestational diabetes mellitus in Korea. Int J gynecol Obstet. 1995. 51:115–122.

11. Buchanan TA. Pancreatic β-cell defects in gestational diabetes: Implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab. 2001. 86:989–993.

12. Palmer JP. What is the best way to predict IDDM? Lancet. 1994. 343:1377–1378.

13. Petersen JS, Dyrberg T, Damm P, Kuhl C, Molsted-Pedersen L, Buschard K. GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy. Diabetologia. 1996. 39:1329–1333.

14. Tuomilehto J, Zimmet P, Mackay IR, Koskela P, Vidgren G, Toivanen L, Tuomilehto-Wolf E, Kohtamaki K, Stengard J, Rowley MJ. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet. 2001. 343:1383–1385.

15. Dozio N, Beretta A, Belloni C, Castiglioni M, Rosa S, Bosi E, Bonifacio E. Low prevalence of islet autoantibodies in patients with gestational diabetes mellitus. Diabetes Care. 1997. 20:81–83.

16. Huh KB, Lee HC, Kim HM, Cho YW, Kim YL, Lee KW, Lee EJ, Lim SK, Kim DH, Yoon JW. Immunogenetic and nutritional profile in insulin-using youth-onset diabetics in Korea. Diabetes Res Clin Pract. 1992. 16:63–70.

17. Ahn CW, Kim HS, Nam JH, Song YD, Lim SK, Kim KR, Lee HC, Huh KB. Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients. Diabet Med. 2002. 19:227–233.

18. Chuang LM, Tsai ST, Huang BY, Tai TY. Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia--a cross-sectional survey of 24317 patients with diabetes mellitus in 1998. Diabet Med. 2002. 19:978–985.

19. Stenstrom G, Gottsater A, Bakhtadze E, Berger B, Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes. 2005. 54:Suppl. 2. S68–S72.